Ten milligrams starts a clock, not a mood switch
Registration packages and the meta-analyses that pooled them did not score 'felt better at breakfast' as a primary endpoint. They scored HAM-D or MADRS change after a pre-specified number of weeks.
A 10 mg Prozac chip is a common start when the prescriber wants less early jitter - older adults, panic-leaning depression, or anyone who already had activation on 20 mg. The usual adult depression target in the same label is 20 mg. The starter is a ramp, not a finished dose.
Taylor's 2006 pooled analysis and later onset papers found some separation from placebo by week one or two on rating scales. Patients feel nausea or a wired sleep before they feel a mood lift. That order is the file. It is not a broken start.
Dr. Priya Nair keeps the onset curve and the CYP2D6 interaction column on the same blotter. She does not adjust your capsule from here.
Stopping at day four because the kitchen still feels heavy is reading a morning the packages never used as a verdict.
Panic-disorder starts often sit at 10 mg longer because early jitter can mimic the panic the chip is meant to quiet. That is a different indication clock. Do not copy it onto a major-depression file without saying so.
Placebo slopes that shrink the printed lift
Kirsch-era arguments and later re-analyses showed large placebo slopes in milder depression, which shrinks the average drug-placebo gap on HAM-D. That does not make the 10 mg chip a sugar pill in moderate-to-severe episodes. It does mean a two-point mean difference can be both statistically real and easy to miss in a single kitchen.
Waiting-list controls look worse than pill placebo. Meta-analyses that mix those arms will inflate apparent lift. Read the comparator before you quote a headline percentage.
Industry-era fluoxetine trials exist. So do independent ones. Cochrane-style grading matters more than a logo on the PDF. A single dramatic case report does not move a pooled onset curve.
If the episode is bipolar depression, an unguarded 10 mg SSRI is a different risk file. This page assumes unipolar major depression unless a clinician says otherwise.
Mild-episode kitchens show the smallest gap. Therapy, sleep, alcohol, and a thyroid check belong on that card before anyone treats a two-point HAM-D mean as a personal promise.
Norfluoxetine still in the file after the last capsule
Parent fluoxetine hangs around for days. Norfluoxetine hangs around for one to two weeks. Together they explain the long washout before an MAOI and the way CYP2D6 substrates - some beta-blockers, tricyclics, tamoxifen - rise while the chip is on board.
A 10 mg start does not make those interactions cute. Inhibition is dose-linked but present. List the other bottles before the first Prozac week, not after a slow heart rate on metoprolol.
Weekly 90 mg delayed-release exists for adherence. It is not a milligram-for-milligram stunt you invent from a 10 mg starter without a prescriber converting the math.
Pain ledgers that use gabapentin do not share this onset curve - different receptor, different clock. If both sit on one card, say so. The Neurontin 400 mg line is a separate file. Stop or switch only with the clinician who can see you - read the ledger disclaimer first.
Tamoxifen clinics sometimes switch the SSRI because CYP2D6 inhibition can cut endoxifen. A 10 mg 'tiny' start does not erase that column. Oncology and psychiatry need the same list.
Why pooled HAM-D waits until week six
Most major-depression fluoxetine trials locked the primary look at week six or eight because that is when drug-placebo separation on HAM-D was large enough to power. Earlier weeks were secondary peeks, not the bet the sample size was built on.
A 50 percent HAM-D drop is the usual 'response' stamp. Remission sits lower on the same scale and is harder. Meta-analyses that only shout response will look sunnier than the remission column the patient actually wanted.
STAR*D later reminded everyone that real-world remission after a first SSRI is modest once you leave the registration rooms. Persistence and a planned switch beat a day-ten mood diary.
If nothing has moved at six to eight weeks on a documented 20 mg - or on 10 mg that was never raised - the file supports a change conversation. It does not support a silent stop in week two.
MADRS pooled looks sit on the same week-six peg in many modern papers. Switching the scale does not move the clock. A kitchen that scores itself daily will still outrun both instruments.
Early jitter on 10 mg is not a failed file
Insomnia, restlessness, loose stool, and a tight jaw show up before anhedonia moves. The 10 mg start exists partly to make that week survivable. Taking the capsule in the morning can spare sleep. A short clinician-directed sleep aid in week one is not a moral failure.
Akathisia-like restlessness is a call, not a 'push through' slogan - especially in younger patients under the boxed warning. The onset curve assumes someone is watching the first month, not a mailbox refill with no follow-up.
Sexual flattening and blunted crying can arrive later than nausea. They belong in the week-six review, not as a surprise at month four. Dose and indication still sit with the prescriber.
Caffeine stacked on a new 10 mg chip makes jitter look like 'Prozac rage' when it is two stimulants in one kitchen.
Morning dosing spares sleep for most starters. A 10 mg night dose that wrecks sleep will fake a failed onset week. Move the clock on the bottle before you retire the molecule.
Network ranks without crowning Prozac first
Cipriani's 2018 Lancet network meta-analysis put every included antidepressant ahead of placebo on average, with fluoxetine in the middle of the pack on efficacy and toward the tolerable side on dropouts. That is a class result, not a trophy for the oldest brand.
Fluoxetine has more published trials than some cousins. Naive league tables that simply count papers will crown it. Network models that adjust for that pile do not.
Half-life is the distinctive column: parent plus norfluoxetine linger. Missed doses hurt less. Switches to an MAOI wait about five weeks. That pharmacokinetic stamp is why 10 mg still matters after the last swallow - see the washout section.
Comorbidity picks the chip more honestly than a rank. Panic, adherence risk, and CYP2D6 comedications can justify fluoxetine. A wish to 'feel it today' cannot.
Drop-out ranks in Cipriani favoured tolerability for several cousins. Fluoxetine's long tail helps missed doses and hurts fast switches. That is a practical column, not a beauty contest.
Boxed early weeks in younger patients
The 2004 boxed warning on suicidality in children, adolescents, and young adults still shapes the first-month calendar. Meta-analyses of paediatric SSRI trials drove that ink. Adult packages were less dramatic and still inherited closer follow-up as practice.
Activation, new agitation, or sudden calm after severe despair in those early weeks is a same-week call. It is not proof the meta-file 'failed.' It is the window the warning asked us to watch.
Fluoxetine remains one of the few SSRIs with a paediatric depression label in the US. That is not a reason to mail 10 mg to a teenager from a study page. It is a reason the onset file includes extra eyes.
Adults over 25 still get a follow-up plan. Mailbox-only starts are how onset side effects get mistaken for 'the depression getting worse' with nobody to call.
Parents should keep a same-week phone plan if a 10 mg chip is started in a minor. The boxed window is a calendar, not a paragraph to skip because the capsule is 'only ten.'
File onset as a curve, not a morning flip
THL-S12 files Prozac 10 mg as a starter chip on a week-six HAM-D clock. Meta-analyses show a real average lift, a large placebo slope in milder episodes, and side effects that arrive before mood.
Early jitter is expected. Early silence on suicide questions is not. Norfluoxetine keeps the interaction column open after the last capsule.
This desk pools papers. It does not open a blister. Bring the week count, the other bottles, and any new agitation to your own clinician.
File the 10 mg morning as a start of a curve. Anyone promising an overnight mood flip is selling a different product than the meta-analyses measured.
Sleep, alcohol, and the other bottles change the curve more than a brand argument. Bring those three facts to the week-two visit. Leave the league table at home.
A 10 mg chip that was never raised is an unfinished depression protocol in most adult packages. Ask the step-up date out loud so week eight has a dose to judge, not a rumor.
Week-two visits exist to catch agitation, not to grade mood. If the only question at that visit is 'do you feel happy yet,' the onset file is being read backwards.
Talk with your own clinician or pharmacist before you change a tablet or a dose. Open the ledger disclaimer.
Updated: